Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1975 1
1976 2
1977 2
1978 1
1979 2
1980 6
1981 10
1982 5
1983 6
1984 3
1985 1
1986 6
1987 4
1988 4
1989 2
1990 3
1991 3
1992 5
1993 5
1994 3
1995 4
1996 3
1997 3
1998 1
1999 4
2000 2
2001 2
2002 3
2003 11
2004 8
2005 9
2006 11
2007 6
2008 6
2009 15
2010 15
2011 17
2012 21
2013 20
2014 16
2015 14
2016 12
2017 8
2018 6
2019 8
2020 9
2021 7
2022 7
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

292 results

Results by year

Filters applied: . Clear all
Page 1
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y. Taylor PC, et al. Among authors: keystone ec. N Engl J Med. 2017 Feb 16;376(7):652-662. doi: 10.1056/NEJMoa1608345. N Engl J Med. 2017. PMID: 28199814 Free article. Clinical Trial.
Reply.
Fatima S, Schieir O, Keystone EC, Valois MF, Bartlett SJ, Bessette L, Boire G, Hazlewood G, Hitchon C, Tin D, Thorne C, Bykerk VP, Pope JE; CATCH Investigators. Fatima S, et al. Among authors: keystone ec. Arthritis Rheumatol. 2022 Jan;74(1):178-180. doi: 10.1002/art.41918. Epub 2021 Dec 6. Arthritis Rheumatol. 2022. PMID: 34224658 No abstract available.
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
Combe B, Kivitz A, Tanaka Y, van der Heijde D, Simon JA, Baraf HSB, Kumar U, Matzkies F, Bartok B, Ye L, Guo Y, Tasset C, Sundy JS, Jahreis A, Genovese MC, Mozaffarian N, Landewé RBM, Bae SC, Keystone EC, Nash P. Combe B, et al. Among authors: keystone ec. Ann Rheum Dis. 2021 Jul;80(7):848-858. doi: 10.1136/annrheumdis-2020-219214. Epub 2021 Jan 27. Ann Rheum Dis. 2021. PMID: 33504485 Free PMC article. Clinical Trial.
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.
Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK. Weinblatt ME, et al. Among authors: keystone ec. Arthritis Rheum. 2003 Jan;48(1):35-45. doi: 10.1002/art.10697. Arthritis Rheum. 2003. PMID: 12528101 Free article. Clinical Trial.
Rheumatoid arthritis: where are we now?
Smolen J, Keystone EC. Smolen J, et al. Among authors: keystone ec. Rheumatology (Oxford). 2012 Jul;51 Suppl 5:v1-2. doi: 10.1093/rheumatology/kes112. Rheumatology (Oxford). 2012. PMID: 22718921 No abstract available.
Intravenous golimumab in rheumatoid arthritis.
Cohen MD, Keystone EC. Cohen MD, et al. Among authors: keystone ec. Expert Rev Clin Immunol. 2014 Jul;10(7):823-30. doi: 10.1586/1744666X.2014.918847. Epub 2014 May 15. Expert Rev Clin Immunol. 2014. PMID: 24831189 Review.
Arthritis clinical trials at a crossroad.
Pope JE, Thorne JC, Haraoui BP, Karsh J, Keystone EC, Bennett L. Pope JE, et al. Among authors: keystone ec. J Rheumatol. 2015 Jan;42(1):14-7. doi: 10.3899/jrheum.140717. J Rheumatol. 2015. PMID: 25554805 No abstract available.
292 results